Now Playing
Alzheimer's Immune Switch, Pancreatic Cancer Doubles Survival & Gravitational Mass Gap
Audio is available on Spreaker — see link below.
Three independent labs converge on neuroinflammation as Alzheimer's primary driver, while a targeted pill nearly doubles pancreatic cancer survival at ASCO 2026. Today's briefing covers the science reshaping oncology and astrophysics.
Audio is available on Spreaker — see link below.
Three independent research teams, working from completely different angles, have converged this week on the same conclusion about Alzheimer's disease: the brain's own immune system isn't just a bystander. It's a driver.
Running parallel to that, the largest genetic study of Alzheimer's to date identified forty-eight previously unknown genes linked to the disease, bringing the confirmed total to one hundred and twenty-seven. The study drew on roughly one hundred and ten thousand patients and two point six million controls.
The third piece of this convergence comes from USC, where researchers screened billions of molecules computationally to identify compounds targeting an enzyme called cPLA2. Their leading candidate reduced inflammation in human brain cells and crossed the blood-brain barrier in mice.
Shifting to oncology. At ASCO twenty twenty-six, Revolution Medicines presented results for daraxonrasib, a targeted pill for metastatic pancreatic cancer, showing it nearly doubled survival compared to standard chemotherapy.
Two more oncology results are worth tracking together, because they reflect the same underlying shift in how cancer treatment is being designed. A genomic test called Prosigna, validated in the OPTIMA trial across six countries, now allows clinicians to identify breast cancer patients who can safely skip chemotherapy entirely, sparing more than five thousand patients in the UK annually from treatment they don't need.
One result outside medicine. The LIGO-Virgo-KAGRA collaboration confirmed a predicted gap in black-hole masses using gravitational wave data.
Chapter summary auto-generated from the verified script. Listen to the full episode for the complete content.